Horizon Therapeutics (HZNP) Misses Q2 EPS by 26c

Horizon Therapeutics (NASDAQ: HZNP) reported Q2 EPS of $1.07, $0.26 worse than the analyst estimate of $1.33. Revenue for the quarter came in at $876.4 million versus the consensus estimate of $936.11 million.

GUIDANCE:

Horizon Therapeutics sees FY2022 revenue of $3.53-3.6 billion, versus the consensus of $3.96 billion.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c